The NPC1L1 Inhibitor Ezetimibe in the Treatment of the Dyslipidemia in Patients Affected by the Metabolic Syndrome: Evidences and Perspectives

Publisher： Bentham Science Publishers

E-ISSN： 1875-6662|4|3|109-120

ISSN： 1573-4080

Source： Current Enzyme Inhibition, Vol.4, Iss.3, 2008-10, pp. : 109-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NPC1L1 and SR-BI are Involved in Intestinal Cholesterol Absorption from Small-Size Lipid Donors

By Haikal Ziad

Lipids, Vol. 43, Iss. 5, 2008-05 ,pp. : 401-408

Springer Publishing Company

Access to resources Recommend Favorite

Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review

By Kidambi S. Patel S. B.

Xenobiotica, Vol. 38, Iss. 7-8, 2008-07 ,pp. : 1119-1139

Informa Healthcare

Access to resources Recommend Favorite

Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome

By Shang Fu-Jun Wang Jie-Pin Liu Xiong-Tao Zheng Qiang-Sun Xue Yu-Sheng Wang Bin Zhao Lian-You

Biomarkers, Vol. 16, Iss. 8, 2011-12 ,pp. : 657-662

Informa Healthcare

Access to resources Recommend Favorite

Proteins that bind and move lipids: MsbA and NPC1

By King Gavin Sharom Frances J.

Critical Reviews in Biochemistry and Molecular Biology, Vol. 47, Iss. 1, 2012-02 ,pp. : 75-95

Informa Healthcare

Access to resources Recommend Favorite

Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis

By Fleischmann Roy Stern Richard Iqbal Imran

Expert Opinion on Biological Therapy, Vol. 4, Iss. 8, 2004-08 ,pp. : 1333-1344

Informa Healthcare

Access to resources Recommend Favorite